Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
AstraZeneca
Citi
Deloitte
Colorcon
QuintilesIMS
Baxter
US Army
Medtronic

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021852

« Back to Dashboard

NDA 021852 describes TACLONEX, which is a drug marketed by Leo Pharma As and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TACLONEX profile page.

The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene hydrate. There are sixty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene hydrate profile page.
Summary for 021852
Tradename:TACLONEX
Applicant:Leo Pharma As
Ingredient:betamethasone dipropionate; calcipotriene hydrate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021852
Ingredient-typeVitamin D
Mechanism of ActionCorticosteroid Hormone Receptor Agonists
Suppliers and Packaging for NDA: 021852
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-989 45802-989-01 50 CARTON in 1 CASE (45802-989-01) > 1 TUBE in 1 CARTON > 100 g in 1 TUBE
TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-989 45802-989-96 100 CARTON in 1 CASE (45802-989-96) > 1 TUBE in 1 CARTON > 60 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;TOPICALStrength0.064%;0.005%
Approval Date:Jan 9, 2006TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Dec 23, 2017
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ SubscribePatent Expiration:Jan 27, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:PSORIASIS
Patent:➤ SubscribePatent Expiration:Jan 27, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF MODERATE PLAQUE PSORIASIS

Expired US Patents for NDA 021852

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 ➤ Subscribe ➤ Subscribe
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 ➤ Subscribe ➤ Subscribe
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Merck
Johnson and Johnson
Mallinckrodt
Fish and Richardson
Deloitte
Moodys
Farmers Insurance
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot